Stock Analysis on Net
Stock Analysis on Net

AstraZeneca PLC (NYSE:AZN)

$22.49

This company has been moved to the archive! The financial data has not been updated since March 10, 2015.

Income Statement

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Paying users area

Try for free

AstraZeneca PLC pages available for free this week:

The data is hidden behind: . Unhide it.

  • Get 1-month access to AstraZeneca PLC for $22.49, or

  • get full access to the entire website for at least 3 months from $62.19.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

AstraZeneca PLC, consolidated income statement

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Revenue
Cost of sales
Gross profit
Distribution costs
Research and development expense
Selling, general and administrative costs
Profit on disposal of subsidiary
Royalties
Impairment
Net gain (loss) on disposal of non-current assets
Gains on disposal of product rights
Net loss on disposal of other intangible assets
Other income
Other expense
Other operating income and expense
Operating profit
Returns on fixed deposits and equity securities
Returns on short-term deposits
Expected return on post-employment defined benefit plan assets
Fair value gains on debt, interest rate swaps and investments
Net exchange gains
Finance income
Interest on debt and commercial paper
Interest on overdrafts, finance leases and other financing costs
Net interest on post-employment defined benefit plan net liabilities
Fair value charges on debt, interest rate swaps and investments
Net exchange losses
Discount unwind on contingent consideration arising on business combinations
Discount unwind on other long-term liabilities
Finance expense
Share of after tax losses in joint ventures
Profit before tax
Taxation
Profit for the period
Profit attributable to non-controlling interests
Profit attributable to owners of the Parent

Based on: 20-F (reporting date: 2014-12-31), 20-F (reporting date: 2013-12-31), 20-F (reporting date: 2012-12-31), 20-F (reporting date: 2011-12-31), 20-F (reporting date: 2010-12-31).

Income statement item Description The company
Revenue Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. AstraZeneca PLC revenue decreased from 2012 to 2013 but then slightly increased from 2013 to 2014.
Operating profit The net result for the period of deducting operating expenses from operating revenues. AstraZeneca PLC operating profit decreased from 2012 to 2013 and from 2013 to 2014.
Profit before tax Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. AstraZeneca PLC profit before tax decreased from 2012 to 2013 and from 2013 to 2014.
Profit attributable to owners of the Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. AstraZeneca PLC profit attributable to owners of the Parent decreased from 2012 to 2013 and from 2013 to 2014.